However, the efficacy of ivonescimab in managing EGFR-TKI–resistant NSCLC with MPE, particularly in cases exhibiting complex molecular features such as high PD-L1 expression and numerous co-occurring genomic alterations, remains unestablished. Here, EGFR is linked to non-small cell lung carcinoma.